Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 103

1.

STF-62247 accumulates in lysosomes and blocks late stages of autophagy to selectively target von Hippel-Lindau-inactivated cells.

Bouhamdani N, Comeau D, Cormier K, Turcotte S.

Am J Physiol Cell Physiol. 2019 May 1;316(5):C605-C620. doi: 10.1152/ajpcell.00483.2018. Epub 2019 Feb 13.

PMID:
30758995
2.
3.

A molecule targeting VHL-deficient renal cell carcinoma that induces autophagy.

Turcotte S, Chan DA, Sutphin PD, Hay MP, Denny WA, Giaccia AJ.

Cancer Cell. 2008 Jul 8;14(1):90-102. doi: 10.1016/j.ccr.2008.06.004.

4.

Quantitative proteomics to study a small molecule targeting the loss of von Hippel-Lindau in renal cell carcinomas.

Bouhamdani N, Joy A, Barnett D, Cormier K, Léger D, Chute IC, Lamarre S, Ouellette R, Turcotte S.

Int J Cancer. 2017 Aug 15;141(4):778-790. doi: 10.1002/ijc.30774. Epub 2017 May 25.

5.

4-Pyridylanilinothiazoles that selectively target von Hippel-Lindau deficient renal cell carcinoma cells by inducing autophagic cell death.

Hay MP, Turcotte S, Flanagan JU, Bonnet M, Chan DA, Sutphin PD, Nguyen P, Giaccia AJ, Denny WA.

J Med Chem. 2010 Jan 28;53(2):787-97. doi: 10.1021/jm901457w.

6.

Targeting lysosome function causes selective cytotoxicity in VHL-inactivated renal cell carcinomas.

Bouhamdani N, Comeau D, Coholan A, Cormier K, Turcotte S.

Carcinogenesis. 2019 Sep 26. pii: bgz161. doi: 10.1093/carcin/bgz161. [Epub ahead of print]

PMID:
31556451
7.

SAR studies of 4-pyridyl heterocyclic anilines that selectively induce autophagic cell death in von Hippel-Lindau-deficient renal cell carcinoma cells.

Bonnet M, Flanagan JU, Chan DA, Lai EW, Nguyen P, Giaccia AJ, Hay MP.

Bioorg Med Chem. 2011 Jun 1;19(11):3347-56. doi: 10.1016/j.bmc.2011.04.042. Epub 2011 Apr 24.

9.

Protective function of von Hippel-Lindau protein against impaired protein processing in renal carcinoma cells.

Gorospe M, Egan JM, Zbar B, Lerman M, Geil L, Kuzmin I, Holbrook NJ.

Mol Cell Biol. 1999 Feb;19(2):1289-300.

10.

Transcription-dependent nuclear-cytoplasmic trafficking is required for the function of the von Hippel-Lindau tumor suppressor protein.

Lee S, Neumann M, Stearman R, Stauber R, Pause A, Pavlakis GN, Klausner RD.

Mol Cell Biol. 1999 Feb;19(2):1486-97.

11.

Mutated Von Hippel-Lindau-renal cell carcinoma (RCC) promotes patients specific natural killer (NK) cytotoxicity.

Trotta AM, Santagata S, Zanotta S, D'Alterio C, Napolitano M, Rea G, Camerlingo R, Esposito F, Lamantia E, Anniciello A, Botti G, Longo N, Botti G, Pignata S, Perdonà S, Scala S.

J Exp Clin Cancer Res. 2018 Dec 4;37(1):297. doi: 10.1186/s13046-018-0952-7.

12.

Radiosensitization of renal cell carcinoma in vitro through the induction of autophagy.

Anbalagan S, Pires IM, Blick C, Hill MA, Ferguson DJ, Chan DA, Hammond EM.

Radiother Oncol. 2012 Jun;103(3):388-93. doi: 10.1016/j.radonc.2012.04.001. Epub 2012 Apr 30.

PMID:
22551566
13.

Identification of cyclin D1 and other novel targets for the von Hippel-Lindau tumor suppressor gene by expression array analysis and investigation of cyclin D1 genotype as a modifier in von Hippel-Lindau disease.

Zatyka M, da Silva NF, Clifford SC, Morris MR, Wiesener MS, Eckardt KU, Houlston RS, Richards FM, Latif F, Maher ER.

Cancer Res. 2002 Jul 1;62(13):3803-11. Erratum in: Cancer Res. 2015 Sep 15;75(18):3993.

14.

Rho-associated kinase 1 inhibition is synthetically lethal with von Hippel-Lindau deficiency in clear cell renal cell carcinoma.

Thompson JM, Nguyen QH, Singh M, Pavesic MW, Nesterenko I, Nelson LJ, Liao AC, Razorenova OV.

Oncogene. 2017 Feb 23;36(8):1080-1089. doi: 10.1038/onc.2016.272. Epub 2016 Nov 14.

17.

The von Hippel-Lindau tumor suppressor gene inhibits hepatocyte growth factor/scatter factor-induced invasion and branching morphogenesis in renal carcinoma cells.

Koochekpour S, Jeffers M, Wang PH, Gong C, Taylor GA, Roessler LM, Stearman R, Vasselli JR, Stetler-Stevenson WG, Kaelin WG Jr, Linehan WM, Klausner RD, Gnarra JR, Vande Woude GF.

Mol Cell Biol. 1999 Sep;19(9):5902-12.

18.

Targeting the loss of the von Hippel-Lindau tumor suppressor gene in renal cell carcinoma cells.

Sutphin PD, Chan DA, Li JM, Turcotte S, Krieg AJ, Giaccia AJ.

Cancer Res. 2007 Jun 15;67(12):5896-905.

19.

Distinct von Hippel-Lindau gene and hypoxia-regulated alterations in gene and protein expression patterns of renal cell carcinoma and their effects on metabolism.

Leisz S, Schulz K, Erb S, Oefner P, Dettmer K, Mougiakakos D, Wang E, Marincola FM, Stehle F, Seliger B.

Oncotarget. 2015 May 10;6(13):11395-406.

20.

Targeting HIF2α translation with Tempol in VHL-deficient clear cell renal cell carcinoma.

Sourbier C, Srivastava G, Ghosh MC, Ghosh S, Yang Y, Gupta G, Degraff W, Krishna MC, Mitchell JB, Rouault TA, Linehan WM.

Oncotarget. 2012 Nov;3(11):1472-82.

Supplemental Content

Support Center